Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
CNBC - 2024-04-17T10:15:01.000Z

The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit it to the Food and Drug Administration mid-year. Read this story